Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 286 of 286 publications.

Sorensen HT, Pedersen L, Nogard L, Fonager K, Rothman KJ. Does month of birth affect risk of Crohn's disease in childhood and adolescence? BMJ. 2001 Jan 1;323(7318):907.

Finkelstein E, Neighbors DM, Bradley C, Candrilli SD. Medical resource utilization and costs of distinct episodes of colon cancer. Poster presented at the 2nd European Conference on the Economics of Cancer; September 2000. Brussels, Belgium.

Watson ME, Lacey LA, McSorley DJ, Kong NS, Northcutt AR, Mangel AW. Patient satisfaction with alosetron for the treatment of irritable bowel syndrome (IBS). Poster presented at the Digestive Disease Week and the 101st Annual Meeting of the American Gastroenterological Association; May 2000. [abstract] Gastroenterology. 2000 Apr; 118((4) Part 1):A219.

Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.

Sacco P, Katz J, Ulanday N. Treatment of skilled nursing facility residents with Resurfix. Poster presented at the American Society of Consultant Pharmacists; January 2000. Chicago, IL.

Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.

Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.

Mangel AW, Camilleri M, Chey WY, Hamm LR, Harding JP, Lawler C, McSorley DJ. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist. Am J Gastroenterol. 1999;116:G4505.

Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.

Mangel AW, Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath AT, McSorley DJ. Alosetron, a 5-HT3 receptor antagonist, in the treatment of non-constipated female IBS patients. Am J Gastroenterol. 1999;94(9):2677.

Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. Am J Gastroenterol. 1998 Dec;93(12):2501-7.

Vakil N, McSorley DJ, Hahn BA. Clarithromycin-resistant helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998 Sep;93(9):1432-5.

Lanza FL, Sontag SJ, Ciociola AA, Sykes DL, Heath AT, McSorley DJ. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter. 1998 Sep;3(3):212-21.

Graham DY, Breiter JR, Ciociola AA, Sykes DL, McSorley DJ. An alternative non-macrolide, non-imidazole treatment for curing helicobacter pylori and duodenal ulcers: ranitidine bismuth citrate plus amoxicillin. Helicobacter. 1998 Jun;3(2):125-31.

Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.

Calvet X, Navarro M, Gil M, Mas P, Rivero E, Sanfeliu I. Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. J Hepatol. 1997 Jun;26(6):1249-54.

Vakil N, McSorley DJ. Reflux symptoms after h. pylori treatment in duodenal ulcer. Poster presented at the British Society of Gastroenterology Diamond Jubilee Meeting; March 1997. [abstract] Gut. 1997 Jan; 40(Suppl 1):A128.

Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.

Perschy TB, McSorley DJ. Ranitidine bismuth citrate in combination with clarithromycin is effective against h. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology. 1997;112(4):A257.

Brullet E, Campo R, Calvet X, Coroleu D, Rivero E, Simó Deu J. Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut. 1996 Aug;39(2):155-8. doi: 10.1136/gut.39.2.155

Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22;312(7046):1563-6.

Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.

Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.

Raiford DS, Perez GS, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996 Jan 1;7(1):101-4.

Campo R, Brullet E, Montserrat A, Calvet X, Rivero E, Brotons C. Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Endoscopy. 1995 Nov;27(9):659-64.

Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, the H. pylori Ulcer Group. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of helicobacter pylori and prevention of duodenal ulcer relapse. Poster presented at the Digestive Disease Week and the 95th Annual Meeting of the American Gastroenterological Association; May 1995. [abstract] Gastroenterology. 1995 Apr; 108(4 (Suppl 1)):A190. doi: 10.1016/0016-5085(95)23422-5

Graham DY, Hirshowitz B, Ciociola AA, Sykes DL, McSorley DJ. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease. Am J Gastroenterol. 1995;90(9):638.

Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.

Johnson JA, Euler AR, Northcutt AR, McSorley DJ. Ranitidine 300mg at bedtime is effective for gastric ulcers: a 12-week, multicenter, randomized, double-blind, placebo-controlled comparison. Am J Gastroenterol. 1993;88(7):1071-5.

Marshall B, Ciociola AA, McSorley DJ, Webb DD. Computerized phone-in symptom recording system correlates with patient recorded symptom diary card for patients with non-ulcer dyspepsia. Am J Gastroenterol. 1993;91(9):1992.

Garcia Rodriguez LA, Walker AM, Perez GS. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology. 1992 Jul 1;3(4):337-42.

Bollini P, Garcia Rodriguez LA, Perez GS, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992 Jun 1;152(6):1289-95.

Euler AR, Johnson JA, Dawson D, Kleoudis C, McSorley DJ. A comparison of ranitidine 150mg and placebo administered at bedtime for maintenance of recurrent benign gastric ulcers. Am J Gastroenterol. 1992;87(9):1267.

Aselton P, Jick H, Chentow SJ, Perera DR, Hunter JR, Rothman KJ. Pyloric stenosis and maternal Bendectin exposure. Am J Epidemiol. 1984 Aug;120(2):251-6.

Yolken RH, Bishop (Johannes) CA, Townsend TR, Bolyard EA, Barlett J, Santos GW, Saral R. Infectious gastroenteritis in bone marrow transplant recipients. N Engl J Med. 1982 Apr 29;306(17):1010-2.

Townsend TR, Bolyard EA, Yolken RH, Beschorner WE, Bishop (Johannes) CA, Burns WH, Santos GW, Saral R. Outbreak of coxsackie A1 gastroenteritis: a complication of bone-marrow transplantation. Lancet. 1982 Apr 10;1(8276):820-3.